ALK and non-small cell lung carcinoma: To generate a prognostic score, based on the top 15 proteins, in ALK fusion positive NSCLC patients treated with crizotinib, we applied the single sample Gene Set Enrichment analysis (ssGSEA) method [23], and computed enrichment scores for each patient in our cohort.